Quantum Biopharma (QNTM) Competitors

$6.81 -0.06 (-0.87%)

Closing price 04:00 PM Eastern

Extended Trading

$6.78 -0.02 (-0.37%)

As of 04:34 PM Eastern

QNTM vs. ANVS, ICCC, QTTB, XBIT, and RLYB

Should you buy Quantum Biopharma stock or one of its competitors? MarketBeat compares Quantum Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quantum Biopharma include Annovis Bio (ANVS), ImmuCell (ICCC), Q32 Bio (QTTB), XBiotech (XBIT), and Rallybio (RLYB). These companies are all part of the "pharmaceutical products" industry.

How does Quantum Biopharma compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Annovis Bio's return on equity of -159.43% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-159.43%	-133.49%
Quantum Biopharma	N/A	-941.54%	-224.41%

Annovis Bio presently has a consensus target price of $13.50, indicating a potential upside of 550.92%. Given Annovis Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Annovis Bio is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Annovis Bio is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.40	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Annovis Bio has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

In the previous week, Annovis Bio and Annovis Bio both had 2 articles in the media. Quantum Biopharma's average media sentiment score of 0.62 beat Annovis Bio's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Annovis Bio beats Quantum Biopharma on 9 of the 12 factors compared between the two stocks.

How does Quantum Biopharma compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Quantum Biopharma has a net margin of 0.00% compared to ImmuCell's net margin of -3.76%. ImmuCell's return on equity of -3.60% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-3.76%	-3.60%	-2.30%
Quantum Biopharma	N/A	-941.54%	-224.41%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ImmuCell has higher revenue and earnings than Quantum Biopharma. ImmuCell is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	2.92	-$1.04M	-$0.11	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

ImmuCell has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

In the previous week, ImmuCell had 4 more articles in the media than Quantum Biopharma. MarketBeat recorded 6 mentions for ImmuCell and 2 mentions for Quantum Biopharma. ImmuCell's average media sentiment score of 1.22 beat Quantum Biopharma's score of 0.62 indicating that ImmuCell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmuCell	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ImmuCell beats Quantum Biopharma on 9 of the 12 factors compared between the two stocks.

How does Quantum Biopharma compare to Q32 Bio?

Q32 Bio (NASDAQ:QTTB) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

In the previous week, Q32 Bio and Q32 Bio both had 2 articles in the media. Q32 Bio's average media sentiment score of 0.86 beat Quantum Biopharma's score of 0.62 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Q32 Bio's return on equity of 149.23% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	149.23%	34.50%
Quantum Biopharma	N/A	-941.54%	-224.41%

31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 40.0% of Q32 Bio shares are owned by insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Q32 Bio has higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	1.99	$29.82M	$2.66	2.37
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Q32 Bio has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Q32 Bio presently has a consensus target price of $13.00, indicating a potential upside of 106.35%. Given Q32 Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Q32 Bio is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Q32 Bio beats Quantum Biopharma on 13 of the 14 factors compared between the two stocks.

How does Quantum Biopharma compare to XBiotech?

XBiotech (NASDAQ:XBIT) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

In the previous week, XBiotech had 2 more articles in the media than Quantum Biopharma. MarketBeat recorded 4 mentions for XBiotech and 2 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.62 beat XBiotech's score of -0.20 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XBiotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

XBiotech's return on equity of -27.80% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-27.80%	-26.67%
Quantum Biopharma	N/A	-941.54%	-224.41%

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 30.8% of XBiotech shares are owned by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

XBiotech is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.50	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

XBiotech has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

XBiotech beats Quantum Biopharma on 7 of the 10 factors compared between the two stocks.

How does Quantum Biopharma compare to Rallybio?

Rallybio (NASDAQ:RLYB) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Rallybio had 3 more articles in the media than Quantum Biopharma. MarketBeat recorded 5 mentions for Rallybio and 2 mentions for Quantum Biopharma. Rallybio's average media sentiment score of 0.73 beat Quantum Biopharma's score of 0.62 indicating that Rallybio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Quantum Biopharma has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -54.44% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-54.44%	-50.24%
Quantum Biopharma	N/A	-941.54%	-224.41%

Rallybio has a beta of -1.1, suggesting that its stock price is 210% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

Rallybio has higher revenue and earnings than Quantum Biopharma. Rallybio is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	87.96	-$8.98M	-$2.56	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 10.3% of Rallybio shares are owned by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Rallybio beats Quantum Biopharma on 9 of the 12 factors compared between the two stocks.

Get Quantum Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNTM vs. The Competition

Export

Metric	Quantum Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$26.01M	$3.32B	$6.23B	$12.27B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-0.83	18.06	20.14	25.23
Price / Sales	N/A	283.98	542.44	73.19
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	-18.41	6.72	9.81	6.90
Net Income	-$26.17M	$24.11M	$3.56B	$333.88M
7 Day Performance	39.55%	3.88%	0.33%	0.04%
1 Month Performance	121.82%	-3.02%	-0.98%	1.74%
1 Year Performance	-25.57%	68.84%	36.19%	32.64%

Quantum Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNTM Quantum Biopharma	0.2426 of 5 stars	$6.81 -0.9%	N/A	-16.4%	$26.01M	N/A	N/A	N/A
ANVS Annovis Bio	1.9838 of 5 stars	$2.28 +0.2%	$13.50 +491.1%	+25.2%	$79M	N/A	N/A	3	News Coverage Earnings Report Upcoming Earnings Gap Down
ICCC ImmuCell	0.8715 of 5 stars	$8.89 +1.9%	N/A	+68.2%	$78.89M	$27.64M	N/A	70	News Coverage Earnings Report
QTTB Q32 Bio	3.9058 of 5 stars	$5.14 +2.0%	$13.00 +152.9%	+278.8%	$78.77M	$53.74M	2.23	39
XBIT XBiotech	0.3237 of 5 stars	$2.55 flat	N/A	-13.2%	$77.74M	N/A	N/A	100	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNTM) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quantum Biopharma (QNTM) Competitors

QNTM vs. ANVS, ICCC, QTTB, XBIT, and RLYB

How does Quantum Biopharma compare to Annovis Bio?

Summary

How does Quantum Biopharma compare to ImmuCell?

Summary

How does Quantum Biopharma compare to Q32 Bio?

Summary

How does Quantum Biopharma compare to XBiotech?

Summary

How does Quantum Biopharma compare to Rallybio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quantum Biopharma (QNTM) Competitors

QNTM vs. ANVS, ICCC, QTTB, XBIT, and RLYB

How does Quantum Biopharma compare to Annovis Bio?

Do insiders and institutionals believe in ANVS or QNTM?

Is ANVS or QNTM more profitable?

Do analysts recommend ANVS or QNTM?

Which has higher valuation & earnings, ANVS or QNTM?

Which has more risk and volatility, ANVS or QNTM?

Does the media prefer ANVS or QNTM?

Summary

How does Quantum Biopharma compare to ImmuCell?

Do insiders and institutionals believe in ICCC or QNTM?

Is ICCC or QNTM more profitable?

Do analysts recommend ICCC or QNTM?

Which has higher valuation & earnings, ICCC or QNTM?

Which has more risk and volatility, ICCC or QNTM?

Does the media prefer ICCC or QNTM?

Summary

How does Quantum Biopharma compare to Q32 Bio?

Does the media prefer QTTB or QNTM?

Is QTTB or QNTM more profitable?

Do insiders and institutionals believe in QTTB or QNTM?

Which has higher valuation & earnings, QTTB or QNTM?

Which has more risk and volatility, QTTB or QNTM?

Do analysts recommend QTTB or QNTM?

Summary

How does Quantum Biopharma compare to XBiotech?

Does the media prefer XBIT or QNTM?

Is XBIT or QNTM more profitable?

Do institutionals and insiders believe in XBIT or QNTM?

Which has better valuation and earnings, XBIT or QNTM?

Which has more volatility & risk, XBIT or QNTM?

Do analysts recommend XBIT or QNTM?

Summary

How does Quantum Biopharma compare to Rallybio?

Do analysts recommend RLYB or QNTM?

Does the media prefer RLYB or QNTM?

Is RLYB or QNTM more profitable?

Which has more volatility & risk, RLYB or QNTM?

Which has better valuation and earnings, RLYB or QNTM?

Do institutionals and insiders believe in RLYB or QNTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools